Domain Therapeutics Rebrands as Kainova Therapeutics to Reflect Clinical Growth

Domain Therapeutics has officially changed its name to Kainova Therapeutics, marking a new chapter for the clinical-stage biopharmaceutical company. The rebrand reflects the firm’s expanding global focus and progress in developing therapies that target G Protein-Coupled Receptors, a key class of drug targets in immuno-oncology and inflammation. The new name combines the sense of a decisive moment with innovation and renewal, underscoring the company’s ambition to transform patient outcomes through scientific excellence and an integrated approach to drug discovery and development. Kainova continues to advance a robust pipeline of differentiated therapies designed to address unmet medical needs.

Its clinical programs include candidates such as a Treg-depleting anti-CCR8 antibody in Phase I/II trials and additional targeted modulators in various stages of development. With operations spanning North America, Europe and Australia, Kainova is positioning itself to accelerate growth, strengthen collaborations and enhance value creation as it moves these promising therapies closer to patients. This strategic rebranding aligns the company’s identity with its current clinical momentum and future aspirations in the biopharma landscape.